The new 15,000 square-foot facility, located in North Brunswick, New Jersey can accommodate clients who conduct clinical trials both in and outside the US and is accredited by the College of American Pathologists (CAP), said the firm.
MDS established its first central lab in Toronto 20 years ago and since then it has developed a network of global central laboratory and centralised cardiac safety services for clinical trials across the globe from facilities in Germany, France, Singapore, and China as well as affiliate labs in Argentina, Brazil, and Mexico.
"We established this latest lab to meet the growing demand from clients for a facility in the US that offers both standard and complex testing to support the development of new treatments," said MDS president David Spaight.
In addition to standard safety testing, the new facility can provide esoteric testing including molecular biology, molecular genetics, flow cytometry, and immunoassays.
Furthermore it has received a Level 1 certification from the National Glycohemoglobin Standardisation Program for providing the highest levels of technical precision and accuracy for HbA1c - a standard diabetic test.
Complex tests such as these are being used increasingly in the drug development industry in the evaluation of targeted treatments for conditions such as cancer, autoimmune diseases, diabetes, and immune deficiencies, said the firm.